Portage Biotech Inc. (PRTG)

NASDAQ: PRTG · Real-Time Price · USD

10.15

-0.61 (-5.67%)

At close: May 02, 2025, 3:59 PM

10.49

3.35%

After-hours: May 02, 2025, 05:48 PM EDT

-5.67% (1D)

Bid	10
Market Cap	11.38M
Revenue (ttm)	n/a
Net Income (ttm)	-67.28M
EPS (ttm)	-68.17
PE Ratio (ttm)	-0.15
Forward PE	-1.15
Analyst	n/a

Ask	10.65
Volume	118,253
Avg. Volume (20D)	1,369,603
Open	10.72
Previous Close	10.76
Day's Range	9.88 - 10.39
52-Week Range	2.10 - 23.01
Beta	0.97

About PRTG

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable pep...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 2, 2002

Employees 7

Stock Exchange NASDAQ

Ticker Symbol PRTG

Website https://www.portagebiotech.com

Full Company Profile

Why Price Moved

5 days ago

+27.46%

Portage Biotech shares are trading higher after th... Unlock content with Pro Subscription

1 month ago

+103.82%

Portage Biotech shares are trading higher after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.

News

4 days ago · benzinga.com

Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human tria...

1 month ago · benzinga.com

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.

1 month ago · marketwatch.com

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.